Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Summary

The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration for an individual participant will be up to approximately 11 months. * The treatment duration for an individual participant will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration for an individual participant will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug; no one will be given placebo.

Timeline

Start

2024-08-28

Primary completion

2026-04-07

Completion

2026-04-07

Outcome

Outcome not reported

Stopped: “Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not supporting further development”

Drugs

Indications